The landscape of clinical trials has evolved significantly over the past few decades, especially concerning access for individuals with disabilities. Diabetes, a chronic condition affecting more than 537 million adults worldwide, often qualifies as a disability under various legal frameworks. These laws aim to ensure equitable access to innovative treatments and research opportunities for all. However, despite progress, people with diabetes—particularly those with disabilities related to the condition—still encounter barriers to participation. This article explores how disability laws have shaped and continue to influence diabetic access to clinical trials, the remaining gaps, and what the future holds for inclusive research.

Understanding Diabetes as a Disability

Diabetes is recognized as a disability under the Americans with Disabilities Act (ADA), the Rehabilitation Act, and many other national and international laws. The condition can substantially limit major life activities, including endocrine function, vision, circulation, and mobility. Complications such as neuropathy, retinopathy, kidney disease, and cardiovascular problems further compound disability. Even when well-managed, diabetes may require constant monitoring, medication adjustments, and dietary management—all of which can be considered disabling under legal definitions.

Because of this legal recognition, individuals with diabetes are entitled to reasonable accommodations in employment, public services, and healthcare settings, including clinical research. This status is the foundation for the protections discussed below.

Several laws in the United States and around the world provide protections for people with disabilities seeking participation in clinical trials. While these statutes were not written specifically for research, their language and enforcement have been extended to cover clinical settings. The most influential include the Americans with Disabilities Act, the Rehabilitation Act, the Affordable Care Act, and FDA regulatory guidance.

Americans with Disabilities Act (ADA)

Enacted in 1990, the ADA prohibits discrimination on the basis of disability in all areas of public life, including healthcare and research. Title II covers state and local government entities, which often fund or operate clinical trials. Title III applies to private entities that own, lease, or operate places of public accommodation—this includes hospitals, clinics, and research facilities.

For diabetic participants, the ADA requires that researchers and sponsors provide reasonable accommodations unless doing so would fundamentally alter the nature of the trial or create an undue burden. Common accommodations include:

  • Accessible parking and entrances for those with mobility impairments
  • Sign language interpreters or captioning for informed consent sessions
  • Materials in alternative formats (braille, large print, audio)
  • Flexible scheduling to accommodate insulin regimens or dialysis appointments
  • Permission to use personal medical devices (e.g., continuous glucose monitors or insulin pumps) during the trial if not contraindicated

The ADA also requires that eligibility criteria do not unnecessarily exclude people with disabilities. For example, a trial for a new diabetic drug should not automatically disqualify participants who use a cane or wheelchair unless the exclusion is essential to the study’s safety or scientific validity.

A landmark case illustrating these protections is Bragdon v. Abbott (1998), where the U.S. Supreme Court held that asymptomatic HIV infection was a disability under the ADA. That reasoning has been applied to other chronic conditions, including diabetes, establishing a precedent for broad interpretation of disability in healthcare settings.

Section 504 of the Rehabilitation Act

Section 504 prohibits discrimination based on disability in any program or activity receiving federal financial assistance. Because many clinical trials are funded through the National Institutes of Health (NIH) or other federal grants, this law is highly relevant. It requires that research sponsors ensure equal access to individuals with disabilities, including those with diabetes.

Section 504 also mandates that facilities be accessible. For diabetic participants with vision loss (diabetic retinopathy), this means signage must be readable and informed consent documents available in large print or audio. For those with peripheral neuropathy affecting mobility, pathways to exam rooms must be wheelchair-accessible. Noncompliance can lead to loss of federal funding, giving institutions a strong incentive to comply.

Affordable Care Act (ACA)

The ACA, enacted in 2010, includes several provisions that indirectly improve clinical trial access for people with diabetes. Section 1557 prohibits discrimination on the basis of race, color, national origin, sex, age, or disability in any health program or activity receiving federal funds. This extends the ADA and Section 504 protections explicitly to health insurance coverage and clinical research.

Additionally, the ACA requires that group health plans and insurers cover routine patient care costs for participants in approved clinical trials. This removes a significant financial barrier for many diabetics, who might otherwise have to forgo participation due to cost concerns. The law also expanded Medicaid and established health insurance marketplaces, improving overall healthcare access for people with disabilities, which in turn can facilitate trial enrollment.

FDA Regulatory Guidelines

The U.S. Food and Drug Administration (FDA) has increasingly emphasized the importance of inclusive clinical trials. In 2020, the agency issued a final guidance document, “Enhancing the Diversity of Clinical Trial Populations — Eligibility Criteria, Enrollment Practices, and Trial Designs,” which encourages sponsors to design trials that reflect the demographics of the disease population, including individuals with disabilities.

The FDA has also proposed that sponsors submit Race and Ethnicity Diversity Plans for phase 3 trials. While these plans currently focus on racial and ethnic diversity, the agency has signaled plans to expand them to include disability status. The FDA’s diversity guidance explicitly states that eligibility criteria should not be more restrictive than necessary for participant safety, and that accommodations such as home visits or telemedicine should be considered to reduce participation barriers.

Furthermore, the FDA has regulatory authority to require post-market studies that include underrepresented populations, which may prompt sponsors to proactively include people with disabilities earlier in the development process.

How Disability Laws Specifically Benefit Diabetics

The intersection of diabetes and disability is complex because the condition itself can create a range of functional limitations. Disability laws address these through several targeted mechanisms.

Removing Physical Barriers

Diabetes affects an estimated 10.5% of the U.S. population, and among adults aged 65 and older, more than 50% have diabetes-related mobility limitations. Clinical trial sites must be physically accessible under the ADA Standards for Accessible Design. This includes accessible parking, ramps, wide doorways, and exam tables that lower for wheelchair users. Such accommodations are not optional; they are legal requirements.

For diabetics with severe neuropathy or amputations, navigating a standard clinic can be impossible without these modifications. Disability laws therefore directly increase the pool of eligible participants.

Communication Accessibility

Diabetic retinopathy remains a leading cause of adult blindness, and many diabetics also experience hearing loss due to microvascular damage. Effective communication during the informed consent process is not only an ethical necessity but a legal one under the ADA. Research institutions must provide auxiliary aids and services, such as:

  • Qualified sign language interpreters
  • Real-time captioning for video presentations
  • Documents in braille or electronic text
  • Plain-language summaries to ensure comprehension

Failure to provide these aids can render a consent invalid and expose sponsors to legal liability. By mandating accessible communication, disability laws ensure that diabetic participants truly understand the risks and benefits of a trial, which improves both safety and informed decision-making.

Scheduling and Travel Accommodations

Diabetes management involves strict routines: insulin injections at specific times, continuous glucose monitoring, and frequent testing. Rigid trial schedules can conflict with these routines, particularly for individuals who also have other disabilities such as gastroparesis or chronic kidney disease requiring dialysis. The ADA requires that scheduling modifications be considered as reasonable accommodations, unless they impose an undue burden.

For example, a trial may offer evening or weekend visits, or allow participants to see a local clinic rather than traveling to the primary site. Home health visits for certain procedures can also be arranged. These accommodations reduce attrition and make participation more feasible.

Protection from Discrimination

Disability laws explicitly prohibit researchers from excluding diabetic participants solely because they have a disability. This is crucial because some trial designs have historically excluded anyone with a “chronic condition” or “requiring ongoing medication,” which would disproportionately affect diabetics. Under the ADA and Section 504, such blanket exclusions must be justified by a direct threat to health or safety. In practice, this means that a diabetic individual with neuropathy cannot be excluded from a diabetes drug trial simply because of the neuropathy unless the study specifically requires intact peripheral sensation for outcome measurements.

Similarly, diabetics who use insulin pumps or continuous glucose monitors cannot be forced to discontinue these devices during a trial unless the protocol clearly demonstrates that they interfere with study endpoints. The laws protect the right to use necessary medical equipment, which is especially important for type 1 diabetics who rely on technology for daily survival.

Persistent Challenges and Gaps

Despite these legal protections, many diabetics still face significant barriers to clinical trial enrollment. Laws alone cannot address every obstacle, and enforcement remains inconsistent.

Systemic Barriers

Transportation remains a major challenge—especially for diabetics in rural areas or those with mobility impairments. While the ADA requires that public transit be accessible, many trial participants must rely on friends, family, or paid services that may not be wheelchair-accessible or affordable. Telemedicine options have expanded, but not all trials allow remote visits for key procedures.

Financial constraints also persist. Though the ACA mandates coverage of routine care costs, many diabetics still struggle with indirect expenses such as lost wages, childcare, or overnight stays. Sponsors rarely cover these, leaving lower-income participants at a disadvantage.

Additionally, insurance denial remains a barrier. Some insurers classify clinical trial participation as “experimental” and refuse to cover any associated care, despite the ACA’s mandate. This forces some diabetics to choose between potentially life-saving trial participation and their existing insurance coverage.

Lack of Awareness Among Researchers

Many investigators simply do not know their obligations under disability law. A 2022 survey conducted by the National Disability Officer Consortium found that only 38% of clinical trial sites had formal policies on disability accommodations. Even when policies exist, staff may be untrained in how to implement them. For instance, a researcher might unintentionally exclude a diabetic participant with an amputation by assuming the person cannot perform self-monitoring tasks, without considering accommodations like a caregiver assistant or modified devices.

This lack of awareness can lead to inadvertent violations, which in turn discourage participation and create liability risks. Education and training for investigators and institutional review boards are critical to closing this gap.

Inconsistent Enforcement

Federal enforcement of disability laws in clinical research is uneven. The Department of Justice has issued guidance on the ADA and clinical trials, but complaints are often resolved quietly without public reporting. Institutional review boards (IRBs) are supposed to ensure that protocols comply with disability laws, but IRB members usually lack expertise in accessibility. As a result, many accommodations are provided only after a participant specifically requests them—if they know to ask.

Moreover, there are no standardized metrics for tracking disability inclusion in trials. A 2021 study in JAMA found that fewer than 5% of registered interventional trials published data on disability status among participants. Without data, it is impossible to enforce compliance or measure progress.

Data Gaps on Disability Inclusion

The lack of collected data on disability status means that the true extent of underrepresentation remains unknown. Some trials ask about disability only in the context of exclusion criteria (e.g., “Do you have a disability that would interfere?”), rather than proactively recruiting people with disabilities. For diabetics, this can lead to a self-selection bias where only the healthiest and most mobile individuals enroll, skewing results toward a healthier subset of the diabetes population.

Efforts are underway to standardize disability data collection. The NIH now requires that applicants for certain grants submit a “Plan for Inclusion of Individuals with Disabilities” alongside their diversity plans, but implementation is still in early stages.

Future Directions: Innovations and Policy Updates

Recognizing these gaps, stakeholders across the research ecosystem are developing strategies to improve access for diabetics with disabilities.

Decentralized and Virtual Trials

The COVID-19 pandemic accelerated the adoption of decentralized clinical trials (DCTs), which allow participants to complete many study activities from home. For diabetics with mobility limitations, vision loss, or other disabilities, DCTs reduce the need for travel and on-site visits. Remote consent via e-signature, home health visits for blood draws, and telehealth check-ins can all be arranged as reasonable accommodations.

The FDA has issued draft guidance on decentralized trials, emphasizing that they must still comply with disability laws. For example, remote consent platforms must be accessible to screen readers, and home health staff must be trained to work with individuals who have disabilities. When properly designed, DCTs can dramatically lower barriers.

Digital Health Tools and Remote Monitoring

Wearable devices such as continuous glucose monitors, smart insulin pens, and activity trackers can collect high-quality data without requiring frequent clinic visits. These tools are especially beneficial for diabetics with disabilities, as they reduce the burden of self-reporting. However, sponsors must ensure that the devices themselves are accessible—touchscreens must be operable by individuals with limited dexterity; interfaces must be compatible with voice control for those with vision loss.

Sponsors can also provide training and technical support to participants, which is a reasonable accommodation under the ADA. By investing in accessible technology, trials can capture more representative data while respecting participants’ autonomy.

Revised FDA Guidance and Proposed Rule Changes

The FDA is expected to update its diversity guidance to explicitly include disability status. In 2023, the agency announced a broader initiative to advance health equity, which includes evaluating how clinical trial eligibility criteria may disproportionately exclude people with disabilities. The FDA’s draft guidance on race and ethnicity diversity plans may eventually serve as a model for disability diversity plans, requiring sponsors to report the percentage of participants with disabilities and justify any exclusions.

Additionally, the 21st Century Cures Act and subsequent legislation have emphasized patient-focused drug development, which encourages sponsors to incorporate patient input—including from people with disabilities—into trial design. This legal framework supports the creation of more inclusive protocols from the outset.

Role of Patient Advocacy Groups

Organizations such as the American Diabetes Association, JDRF, and the Disability Rights Education and Defense Fund (DREDF) are actively working to improve trial access. They provide educational materials for researchers, offer training for patients on their rights, and advocate for policy reforms. Some groups have developed toolkits for researchers on how to design accessible trials, including checklists for physical, communication, and scheduling accommodations.

Patient advocates also serve on FDA advisory committees and IRBs, bringing lived experience to the review process. Their involvement ensures that disability perspectives are considered when evaluating trial protocols and results.

Why Inclusive Trials Matter for Diabetes Research

Beyond legal compliance, making clinical trials accessible for diabetics with disabilities has profound scientific and ethical implications.

Generalizability of Findings

If clinical trials exclude low-vision diabetics, those with mobility impairments, or those with cognitive effects from hypoglycemia, then the resulting evidence base may not apply to those populations. For instance, a new insulin formulation tested only on highly mobile, visually unimpaired patients may not be safe or effective for the many diabetics who cannot self-administer injections accurately. Inclusive trials produce data that reflect the real-world patient population, leading to better treatment guidelines and fewer post-market adverse events.

Ethical Imperative

Justice in research requires that the burdens and benefits of clinical trials be distributed equitably. Diabetics with disabilities have historically been underrepresented, and their exclusion perpetuates health disparities. Disability laws are not just about preventing discrimination; they are about fulfilling the ethical principles of respect for persons, beneficence, and justice as articulated in the Belmont Report. By proactively including people with disabilities, sponsors demonstrate a commitment to fairness.

Real-World Impact on Patients

For individual diabetics with disabilities, access to clinical trials can mean earlier access to cutting-edge therapies, such as advanced insulin analogues, closed-loop systems, or approaches to prevent complications like diabetic retinopathy. It also gives them a voice in shaping future treatments. Many diabetics report that participating in research empowers them and improves their understanding of their own condition.

Conclusion

The impact of disability laws on diabetic access to clinical trials has been transformative, yet incomplete. The ADA, Rehabilitation Act, ACA, and FDA guidance have laid a strong foundation by prohibiting discrimination and requiring reasonable accommodations. These laws have opened doors for many diabetics who were previously excluded from research opportunities. However, persistent challenges—systemic barriers, lack of researcher awareness, inconsistent enforcement, and data gaps—mean that true equity remains elusive.

Looking forward, decentralized trials, accessible digital health tools, updated FDA policies, and active advocacy hold promise for closing these gaps. Researchers and sponsors must view disability inclusion not as a compliance burden but as a scientific and moral imperative. Only by designing trials that work for all diabetics—including those with disabilities—can we develop treatments that truly serve the entire population. Continued collaboration among lawmakers, regulatory agencies, healthcare providers, and disability advocates will be essential to ensure that the letter of the law becomes the reality of practice.